Early Follicular Supplementation of Ganirelix in IVF 2004

This study has been completed.
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
First received: April 17, 2007
Last updated: June 26, 2008
Last verified: June 2008
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results

Condition Intervention Phase
IVF Treatment
Drug: Ganirelix
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles

Resource links provided by NLM:

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • pregnancy rates [ Time Frame: one cycle ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • differences in hormonal levels [ Time Frame: one cycle ] [ Designated as safety issue: No ]
  • differences in the basic treatment doses [ Time Frame: one cycle ] [ Designated as safety issue: No ]
  • oocyte counts [ Time Frame: one cycle ] [ Designated as safety issue: No ]
  • fertilization rate [ Time Frame: one cycle ] [ Designated as safety issue: No ]
  • cleavage rate [ Time Frame: one cycle ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: January 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
Drug: Ganirelix
sc injection of Ganirelix 0.25 mg per day
No Intervention: 2
Standard Flexible antagonist protocol

Detailed Description:

GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol.

Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.

Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • infertility
  • IVF candidate
  • failure of previous IVF attempt

Exclusion Criteria:

  • low ovarian reserve
  • untreated distortion of uterine cavity
  • medical contraindication for IVF treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00461422

The Baruch Padeh medical center, Poriya
Tiberias, Israel, 15208
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Principal Investigator: Yohnny S Younis, MD The Ministry of Health, Israel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00461422     History of Changes
Other Study ID Numbers: soltsman2004.CTIL
Study First Received: April 17, 2007
Last Updated: June 26, 2008
Health Authority: Israel: Ministry of Health

Keywords provided by The Baruch Padeh Medical Center, Poriya:
GnRH antagonist

Additional relevant MeSH terms:
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on December 01, 2015